Suven Life gets patents for neuro-degenerative drug

The patents are valid up to 2032, the company said

Drug firm Suven Life Sciences has been granted a patent each by Australia, Eurasia, Israel and the US for a drug used in treatment of neuro-degenerative diseases.

In a regulatory filing today, Suven Life said it has "secured product patents in Australia, Eurasia, Israel and the US to their New Chemical Entities (NCEs) for CNS therapy through mechanism of action".

The patents are valid up to 2032, the company added.

The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neuro-degenerative disorders, Suven Life said.

Suven Life CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally."

With these new patents, Suven has a total of 24 granted patents from Australia, 17 from Eurasia and 9 from Israel and 24 from the US.

"These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like phase-I or phase-II," Suven said.

The stock was trading 0.46% up at Rs 208.50 on BSE in the morning trade.